Kranda tapped as Vaccinogen CEO

Vaccinogen has appointed veteran biotechnology executive Michael Kranda as president and CEO to guide it through its next stage of growth. Vaccinogen release

NGM Biopharmaceuticals has named William Rieflin as CEO. He also will serve on the board of directors. NGM release

Thomas Werner has been president and CEO of Accera. Accera release

Roche announced today that Jacques Banchereau has joined Roche as senior VP and head of the inflammation and virology discovery and translational areas. Roche release

James Welch has joined AcelRx Pharmaceuticals as CFO. AcelRx release

Pharming has tapped Karl Keegan as CFO. Pharming release

Altheos, a biopharmaceutical company focused on next generation treatments for glaucoma and ocular hypertension, has announced that Barbara Wirostko has been appointed CMO. Altheos release

Life Technologies has named physician and clinical geneticist Paul Billings as CMO, a newly created position aimed at improving patient care through expanding the use of medically relevant genomic technologies in clinical settings. Life Technologies release

NKT Therapeutics has appointed Barbara Finck to the position of CMO. NKT release

Anacor Pharmaceuticals has tapped Geoffrey Parker as senior VP and CFO. Anacor release

Ugo DeBlasi has joined Celera as senior VP and CFO. Celera release

Unigene Laboratories has expanded the company's leadership team with the appointment of Gregory Mayes to the newly created position of VP, corporate affairs and general counsel, and the promotion of Roxanne Tavakkol to VP, global regulatory affairs, effective immediately. Unigene release

NormOxys has announced that Gerard (Rod) Riedel has been appointed VP, regulatory affairs and program management. NormOxys release

BioClinica, a global provider of clinical trial management services, has tapped Garry Johnson as senior VP and chief technology officer, a newly created position. BioClinica release

Intercell has named Eric Frings as new site director of Intercell Biomedical in Livingston, Scotland. Intercell release

Third Rock Ventures, LLC has appointed Steven Paul to venture partner. Paul is the former president of the Lilly Research Laboratories of Eli Lilly and Company and now leads the Helen & Robert Appel Institute for Alzheimer's Research at Weill Cornell Medical College. Third Rock release

Phytoceuticals has elected Stephen Rietiker as the company's first outside chairman of the board. Phytoceuticals release

AmStem has named Michael Glantz to its scientific and medical board of advisors. AmStem release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.